electronic case report form ecrf (Cardinal Health)
86
Structured Review
Cardinal Health
electronic case report form ecrf
Electronic Case Report Form Ecrf, supplied by Cardinal Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/electronic+case+report+forms/case+electronic+form+report/pm41589579-46-8-2
Average 86 stars, based on 1 article reviews
Electronic Case Report Form Ecrf, supplied by Cardinal Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/electronic+case+report+forms/case+electronic+form+report/pm41589579-46-8-2
Average 86 stars, based on 1 article reviews
electronic case report form ecrf - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. Article Snippet: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by platelet counts (PC) below 100 × 109/L, conferring increased bleeding risk that spans minor to lifethreatening events and contributing to hospitalizations, fatigue and impaired quality of life.1–5 ITP is classified by duration as newly diagnosed (<3 months), persistent (3 to <12 months) or chronic (≥12 months).. Firstline treatments include corticosteroids and immunoglobulins, but many patients become unresponsive to or dependent on steroids.6,7 As per American Society of Hematology (ASH) and international guidelines, thrombopoietin receptor agonists (TPORAs) are recommended as secondline treatment O R I G I N A L P A P E R Article Title: Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer? Article Snippet: Patients and Methods: Participating physicians from the Article Title: Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma Article Snippet: Treating oncologists from the Selection:Article Title: First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Article Snippet: .. In brief, Article Title: First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis Article Snippet: .. In brief, |